Deutsche Bank Ag\ Altimmune, Inc. Transaction History

Deutsche Bank Ag\

$218 Billion
Q2 2024

A detailed history of Deutsche Bank Ag\ transactions in Altimmune, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 40,435 shares of ALT stock, worth $318,627. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,435

Previous 43,588 7.23%

Holding current value

$318,627

Previous $443,000 39.5%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.91 - $10.23 $18,634 - $32,255	-3,153 Reduced 7.23%	40,435 $268,000
Q1 2024 May 15, 2024	SELL	$8.22 - $13.81 $142,189 - $238,885	-17,298 Reduced 28.41%	43,588 $443,000
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $65,180 - $353,921	30,458 Added 100.1%	60,886 $684,000
Q3 2023 Nov 09, 2023	BUY	$2.4 - $3.45 $73,027 - $104,976	30,428 New	30,428 $79,000
Q2 2022 Aug 11, 2022	SELL	$3.94 - $11.77 $85,285 - $254,773	-21,646 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.9 - $9.45 $14,384 - $23,039	-2,438 Reduced 10.12%	21,646 $132,000
Q4 2021 Feb 11, 2022	BUY	$8.69 - $12.48 $11,140 - $15,999	1,282 Added 5.62%	24,084 $221,000
Q3 2021 Nov 04, 2021	BUY	$8.43 - $16.81 $29,572 - $58,969	3,508 Added 18.18%	22,802 $258,000
Q2 2021 Aug 11, 2021	BUY	$9.85 - $16.46 $190,045 - $317,579	19,294 New	19,294 $190,000
Q3 2019 Nov 14, 2019	SELL	$1.95 - $2.66 $195 - $266	-100 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.54 - $4.54 $251 - $449	99 Added 9900.0%	100 $0
Q3 2018 Dec 21, 2021	SELL	$4.27 - $26.23 $4 - $26	-1 Reduced 50.0%	1 $0
Q3 2018 Nov 14, 2018	BUY	$4.27 - $26.23 $8 - $52	2 New	2 $0

Others Institutions Holding ALT

# of Institutions

191

Shares Held

42.4M

Call Options Held

1.05M

Put Options Held

582K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $386M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account